What is CagriSema and can I get it now?
CagriSema is Novo Nordisk's combination of cagrilintide (amylin agonist) plus semaglutide (GLP-1 agonist). Phase 3 REDEFINE-1 readout 2024 showed about 22.7 percent mean weight loss at 2.4 mg of each weekly over 68 weeks. Not yet approved as of April 2026; off-label research-chem is the only access path today.
Last reviewed · Panya.health editorial
How it works vs tirzepatide
CagriSema combines two appetite pathways. Cagrilintide is a long-acting amylin analog that signals satiety via the area postrema in the brainstem. Semaglutide is the same GLP-1 agonist already in Wegovy and Ozempic. Both delay gastric emptying. The combination amplifies appetite suppression because the two pathways are independent. The competitive context is that tirzepatide (Mounjaro, Zepbound) hit 22.5 percent in SURMOUNT-1 with a single dual-receptor molecule. CagriSema's 22.7 percent in REDEFINE-1 was below pre-trial market expectations of more than 25 percent.
Where you can get it today
Not approved yet anywhere as of April 2026. Novo Nordisk regulatory submission is underway. The only access path today is research-chem cagrilintide alongside compounded or research-chem semaglutide, run as an off-label combination. Cagrilintide is harder to source than tirzepatide because the lipidation chemistry is non-trivial; supply is thinner and quality control less mature. Most users running this combination today are deep into the research-peptide community.
Risks and titration
GI side effects compound when both components titrate together. Standard escalation mirrors semaglutide: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg over 16 weeks for each component. Pancreatitis and thyroid C-cell tumor signals from semaglutide rodent studies remain labelled contraindications and apply to the combination. Hypoglycemia risk if combined with insulin or sulfonylureas in T2D users. Pregnancy and breastfeeding off-limits.
Read about this peptide
Common pairings
Novo Nordisk's next-gen weight-loss combination. Amylin-receptor agonism (cagrilintide) plus GLP-1 agonism (semaglutide) for synergistic gastric-emptying delay + central satiety amplification.
Common community pairing. Tirzepatide drives caloric deficit; BPC-157 supports gut tolerance + tissue repair through the muscle loss + activity changes that come with rapid weight loss.
Related posts
The three GLP-1 drugs that matter in 2026: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide (Lilly's triple-agonist). How they differ in mechanism, weight loss, side effe...
The real differences between compounded tirzepatide from a 503A pharmacy and brand Mounjaro from Eli Lilly. Regulatory status, quality control, pricing, and when one is clearly better than the other.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.